Cointime

Ablynx

company

About

Ablynx is a biopharmaceutical company engaged in the discovery and development of nanobodies.

  • 251 - 500

Highlights

Total Funding Amount
$80M
Funding Rounds
2
Investors
1

Details

Last Funding Type
Series B
Last Funding Money Raised
$30M
Industries
Biopharma,Biotechnology,Pharmaceutical
Founded date
Jan 1, 2001
Number Of Employee
251 - 500
Operating Status
Active

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 projects in the pipeline and five Nanobodies in clinical development.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$80M
Ablynx has raised a total of $80M in funding over 2 rounds. Their latest funding was raised on Aug 23, 2006 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 23, 2006 Series C $50M 1 — — Detail
Apr 6, 2004 Series B $30M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
1
Ablynx is funded by 1 investors. Biotech Fund Flanders are the most recent investors.
Investor Name Lead Investor Funding Round
Biotech Fund Flanders — Series C
Cointime
เนื้อหา
บริษัท